Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Sell
30
IFRX Quote, Financials, Valuation and Earnings
Last price:
$1.15
Seasonality move
:
2.57%
Day range:
$1.01 - $1.09
52-week range:
$1.01 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
340.46x
P/B ratio:
1.10x
Volume:
565.8K
Avg. volume:
394.3K
1-year change:
-30.92%
Market cap:
$70.5M
Revenue:
$179.4K
EPS (TTM):
-$0.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$37.4K | -$0.19 | -5.26% | -0.05% | $9.24 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | -$0.40 | -- | -82.44% | $42.63 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.49 | -- | -35.68% | $39.86 |
|
QGEN
Qiagen NV
|
$464.8M | $0.49 | 1.31% | 31.38% | $49.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$1.05 | $9.24 | $70.5M | -- | $0.00 | 0% | 340.46x |
|
CDT
Conduit Pharmaceuticals
|
$0.72 | -- | $4.8M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics
|
$26.01 | $42.63 | $716.4M | -- | $1.03 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$9.56 | $39.86 | $357.9M | -- | $19.36 | 0% | -- |
|
QGEN
Qiagen NV
|
$39.50 | $49.80 | $8.5B | 105.61x | $1.30 | 0% | 4.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-- | 4.794 | -- | 3.85x |
|
CDT
Conduit Pharmaceuticals
|
-- | 1.498 | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | 1.895 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -3.805 | -- | -- |
|
QGEN
Qiagen NV
|
28.06% | 0.222 | 14.06% | 2.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-$3M | -$10.4M | -56.78% | -56.78% | 1207051.66% | -$12.3M |
|
CDT
Conduit Pharmaceuticals
|
-- | -$5.8M | -- | -- | -- | -$2M |
|
LENZ
LENZ Therapeutics
|
-- | -$15.2M | -- | -- | -- | -$9.2M |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
QGEN
Qiagen NV
|
$333.3M | $141.2M | 1.63% | 2.33% | 26.28% | $141.9M |
InflaRx NV vs. Competitors
-
Which has Higher Returns IFRX or CDT?
Conduit Pharmaceuticals has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.09 $63.9M CDTConduit Pharmaceuticals-- -$0.07 -- -
What do Analysts Say About IFRX or CDT?
InflaRx NV has a consensus price target of $9.24, signalling upside risk potential of 779.76%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Conduit Pharmaceuticals, analysts believe InflaRx NV is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV4 1 0 CDTConduit Pharmaceuticals0 0 0 -
Is IFRX or CDT More Risky?
InflaRx NV has a beta of 2.206, which suggesting that the stock is 120.591% more volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or CDT?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or CDT?
InflaRx NV quarterly revenues are -$450, which are larger than Conduit Pharmaceuticals quarterly revenues of --. InflaRx NV's net income of -$5.4M is higher than Conduit Pharmaceuticals's net income of -$6.5M. Notably, InflaRx NV's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 340.46x versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV340.46x -- -$450 -$5.4M CDTConduit Pharmaceuticals-- -- -- -$6.5M
-
Which has Higher Returns IFRX or LENZ?
LENZ Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.09 $63.9M LENZLENZ Therapeutics-- -$0.46 -- -
What do Analysts Say About IFRX or LENZ?
InflaRx NV has a consensus price target of $9.24, signalling upside risk potential of 779.76%. On the other hand LENZ Therapeutics has an analysts' consensus of $42.63 which suggests that it could grow by 63.88%. Given that InflaRx NV has higher upside potential than LENZ Therapeutics, analysts believe InflaRx NV is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV4 1 0 LENZLENZ Therapeutics5 0 0 -
Is IFRX or LENZ More Risky?
InflaRx NV has a beta of 2.206, which suggesting that the stock is 120.591% more volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LENZ?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. InflaRx NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LENZ?
InflaRx NV quarterly revenues are -$450, which are larger than LENZ Therapeutics quarterly revenues of --. InflaRx NV's net income of -$5.4M is higher than LENZ Therapeutics's net income of -$12.7M. Notably, InflaRx NV's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 340.46x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV340.46x -- -$450 -$5.4M LENZLENZ Therapeutics-- -- -- -$12.7M
-
Which has Higher Returns IFRX or ORKA?
Oruka Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.09 $63.9M ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About IFRX or ORKA?
InflaRx NV has a consensus price target of $9.24, signalling upside risk potential of 779.76%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.86 which suggests that it could grow by 316.92%. Given that InflaRx NV has higher upside potential than Oruka Therapeutics, analysts believe InflaRx NV is more attractive than Oruka Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV4 1 0 ORKAOruka Therapeutics7 0 0 -
Is IFRX or ORKA More Risky?
InflaRx NV has a beta of 2.206, which suggesting that the stock is 120.591% more volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.582%.
-
Which is a Better Dividend Stock IFRX or ORKA?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. InflaRx NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or ORKA?
InflaRx NV quarterly revenues are -$450, which are larger than Oruka Therapeutics quarterly revenues of --. InflaRx NV's net income of -$5.4M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, InflaRx NV's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 340.46x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV340.46x -- -$450 -$5.4M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns IFRX or QGEN?
Qiagen NV has a net margin of -14092.9% compared to InflaRx NV's net margin of 16.95%. InflaRx NV's return on equity of -56.78% beat Qiagen NV's return on equity of 2.33%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.09 $63.9M QGENQiagen NV63.95% $0.40 $5B -
What do Analysts Say About IFRX or QGEN?
InflaRx NV has a consensus price target of $9.24, signalling upside risk potential of 779.76%. On the other hand Qiagen NV has an analysts' consensus of $49.80 which suggests that it could grow by 26.07%. Given that InflaRx NV has higher upside potential than Qiagen NV, analysts believe InflaRx NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV4 1 0 QGENQiagen NV6 8 0 -
Is IFRX or QGEN More Risky?
InflaRx NV has a beta of 2.206, which suggesting that the stock is 120.591% more volatile than S&P 500. In comparison Qiagen NV has a beta of 0.624, suggesting its less volatile than the S&P 500 by 37.612%.
-
Which is a Better Dividend Stock IFRX or QGEN?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Qiagen NV offers a yield of 0% to investors and pays a quarterly dividend of $1.30 per share. InflaRx NV pays -- of its earnings as a dividend. Qiagen NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or QGEN?
InflaRx NV quarterly revenues are -$450, which are smaller than Qiagen NV quarterly revenues of $521.2M. InflaRx NV's net income of -$5.4M is lower than Qiagen NV's net income of $88.3M. Notably, InflaRx NV's price-to-earnings ratio is -- while Qiagen NV's PE ratio is 105.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 340.46x versus 4.38x for Qiagen NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV340.46x -- -$450 -$5.4M QGENQiagen NV4.38x 105.61x $521.2M $88.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
